Are there any challenges in HCV therapy of HIV infected patients left?

The introduction of highly effective antiretroviral therapy (ART) has dramatically reduced HIV-associated morbidity and mortality. Indeed, near to normal life expectancy can be expected in human immunodeficiency virus (HIV) infections if antiviral therapy is started before the onset of AIDS or advanced immunodeficiency. Therefore, concomitant diseases are increasingly gaining importance. Coinfections with the Hepatitis C virus (HCV) are of substantial concern, as HIV is known to accelerate the progression of HCV related liver disease, which has emerged as a leading cause of death in HIV infected individuals [1].

Source: International Journal of Antimicrobial Agents - August 23, 2018 Category: Drugs & Pharmacology Authors: Jenny Bischoff, J ürgen K Rockstroh Tags: Themed Issue: Therapeutics of hepatitis viruses Source Type: research